The prevailing discourse surrounding antimicrobial resistance (AMR) has long focused on the concept of scarcity, specifically the alarming depletion of the pharmaceutical pipeline. For over a decade, the global health community has sounded the alarm regarding the collapse of antibiotic development economics, documenting a landscape where new drugs are rare and investment is dwindling. Policy discussions have been dominated by "pull incentives," subscription-style payment models, and legislative efforts such as the PASTEUR Act in the United States, which seeks to decouple pharmaceutical revenue from the volume of drugs sold. While these efforts are essential to address the scientific and financial hurdles of drug discovery, a second, more insidious failure remains largely unaddressed: the inability to deliver existing, approved treatments to the patients who need them most.
This "delivery failure" represents a market design flaw where life-saving therapies sit on shelves in one jurisdiction while patients in another perish from resistant infections those very drugs could treat. It is a crisis not of discovery, but of access and infrastructure. Even when the science has succeeded, the systems of regulation, procurement, and distribution often fail to move at the speed of a clinical emergency. For a patient suffering from a pan-resistant bloodstream infection, the difference between a drug that does not exist and a drug that cannot be imported is non-existent; both result in a preventable death.
The Human Cost of Regulatory Fragmentation
The urgency of this issue is often best understood through the lens of individual clinical outcomes that mirror systemic failures. One of the primary advocates for a shift in AMR policy, Diane Shader Smith, has spent years highlighting this gap following the loss of her daughter, Mallory, to a pan-resistant infection. In that instance, the medical infrastructure failed to bridge the gap between a potential therapy and the patient within the critical window of efficacy. This experience is not an isolated tragedy but a representative data point for thousands of families globally. It underscores a fundamental question for policymakers: Is the goal merely to invent new molecules, or is it to ensure those molecules reach the bedside in time to matter?
In the current global health landscape, a drug or a phage preparation authorized in the United States or Europe may remain entirely unavailable in a neighboring or distant jurisdiction. Regulatory pathways are notoriously fragmented, with national health authorities rarely practicing mutual recognition for orphan drugs or novel antimicrobials. This lack of harmonization means that a manufacturer must navigate a bespoke, costly, and time-consuming approval process in every single country it wishes to enter. For a pharmaceutical company, the cost of these regulatory hurdles often outweighs the projected revenue from a drug that is, by design, intended to be used sparingly.
A Chronology of the AMR Crisis and Policy Response
To understand the current impasse, one must look at the timeline of antimicrobial development and the subsequent rise of resistance. The "Golden Age" of antibiotics, spanning from the 1940s to the 1960s, saw the discovery of most of the antibiotic classes in use today. However, by the 1980s, the "discovery void" began as pharmaceutical giants shifted focus toward chronic disease medications that offered higher profit margins.
By 2014, the UK government-commissioned "Review on Antimicrobial Resistance," led by economist Jim O’Neill, estimated that by 2050, 10 million people could die annually from AMR if no action was taken. This report served as a catalyst for international policy. In 2016, the United Nations General Assembly held its first High-Level Meeting on AMR, recognizing it as a fundamental threat to global health security.
In the years following, various "push" and "pull" mechanisms were introduced. The CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) was launched to fund early-stage research, while the UK pioneered a "subscription model" where the government pays a fixed fee for access to antibiotics regardless of how many are prescribed. In 2023 and 2024, the reintroduction of the PASTEUR Act in the U.S. Senate signaled a continued commitment to fixing the "front end" of the pipeline. Yet, throughout this chronology, the "back end"—the logistics of market entry and cross-border delivery—has remained a secondary concern, leaving a significant portion of the global population without access to the few new drugs that have reached the market.
Supporting Data: The Magnitude of the Access Gap
The data surrounding AMR highlights a paradox: while we need new drugs, we are failing to utilize the ones we have. According to the 2022 Global Burden of Bacterial Antimicrobial Resistance (GRAM) report published in The Lancet, AMR was directly responsible for 1.27 million deaths in 2019 and played a role in 4.95 million deaths globally. The highest burden of these deaths occurs in low- and middle-income countries (LMICs), precisely the regions where new, high-cost antimicrobials are least likely to be launched.
A study of 14 new antibiotics approved between 2010 and 2020 found that most were available in fewer than 30 countries. In many instances, even if a drug is approved, it is not stocked. Research indicates that in many LMICs, the availability of "Watch" and "Reserve" category antibiotics (as defined by the WHO) is less than 20%. This is often due to the "stewardship paradox." Stewardship programs are essential to prevent the development of further resistance by restricting the use of new, powerful antibiotics. However, these restrictions suppress sales volume. Under current market conditions, low volume equals low commercial viability, leading manufacturers to bypass markets with high clinical need but low profit potential.
Structural Barriers and Market Design Failures
The failure to deliver antimicrobials is structural, not accidental. Several key barriers turn a solvable clinical situation into a fatal delay:
- Pricing and Reimbursement Stalls: There is often no established pricing precedent for novel antimicrobials that are intended for reserve use. Payers and insurance providers have no reference point, leading to protracted negotiations that can stall a drug’s entry into a market for years.
- Emergency Import Timelines: While many countries have mechanisms for the emergency import of non-registered drugs, these processes are often bureaucratic and slow. A bloodstream infection can turn septic and fatal within 48 to 72 hours, yet emergency import permits often take weeks to process.
- Supply Chain Fragility: Antimicrobials often require specialized handling and temperature-controlled logistics. In regions with underdeveloped infrastructure, the physical movement of these drugs is a significant hurdle.
- The "Access vs. Excess" Dilemma: Global health organizations struggle to balance the need for broad access with the need to prevent "excess" use that drives resistance. This tension often results in cautious procurement strategies that leave hospitals under-equipped.
Analysis of Implications and Necessary Policy Shifts
If the global health community continues to focus solely on the "front of the pipeline," the return on investment for new drugs will remain tragically low. A therapy that exists but cannot reach a patient is, for all practical purposes, a therapy that was never invented. The implications of this failure extend beyond individual patient outcomes; it undermines global health security. Resistance does not respect borders. If a resistant strain emerges in a region where the appropriate "reserve" antibiotic is unavailable, that strain will proliferate and eventually spread to regions where the drug is available, potentially rendering the treatment less effective globally.
To address this, senior policymakers and industry leaders must consider a new framework for AMR strategy. This includes:
- Regulatory Harmonization: Establishing "mutual recognition" agreements where an approval by a stringent regulatory authority (like the FDA or EMA) allows for expedited or automatic temporary authorization in other jurisdictions during public health emergencies.
- Pooled Procurement and Global Stockpiling: Similar to the models used for vaccines, international agencies could create pooled procurement funds to guarantee a market for manufacturers while ensuring that a physical stockpile of reserve antibiotics is strategically located in regional hubs.
- Digital Tracking and Rapid Diagnostics: Enhancing the ability to identify resistant infections quickly through rapid diagnostics is useless if the drug cannot follow the diagnosis. Integrating digital supply chain tracking can help identify where drugs are sitting on shelves and facilitate rapid redistribution.
Conclusion: Redefining Success in AMR Strategy
The measure of a successful antimicrobial resistance strategy cannot be limited to the number of new molecules discovered or the amount of funding injected into R&D. While the PASTEUR Act and similar incentives are vital, they represent only half of the solution. The true measure of success is whether a clinician, faced with a dying patient, can obtain the effective treatment in time to save a life, regardless of their geographic location.
The system currently in place is failing this test. It is failing because it treats antimicrobials as standard commodities rather than essential components of global infrastructure. By shifting focus toward the "back of the pipeline"—prioritizing coordination, standardization, and speed of delivery—institutions can turn the tide on AMR. The solutions to these delivery failures are within reach; they require not a scientific breakthrough, but the political and institutional will to prioritize the logistics of survival. Only then will the promise of modern medicine be fulfilled for those facing the growing threat of drug-resistant infections.
